Korhan Raif, MD
Internal Medicine · Barry, ILNPI 1184697476
Payments from drug & device makers
Across 534 payments — averaging $16.23 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$2K
- Lilly USA, LLC$880
- AstraZeneca$733
- Pfizer$622
- Amgen$578
- E.r. Squibb & Sons, L.L.C.$482
- plus $3K from 29 others
What the payments were for
- Food & beverage$8,38397%
- Education$2823%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 124 | $1,876 |
| Lilly USA, LLC | 60 | $880 |
| AstraZeneca | 39 | $733 |
| Pfizer | 47 | $622 |
| Amgen | 32 | $578 |
| E.r. Squibb & Sons, L.L.C. | 30 | $482 |
| Astellas Pharma US Inc | 18 | $409 |
| Teva Pharmaceuticals USA, Inc. | 14 | $280 |
| Novartis | 13 | $263 |
| Boehringer Ingelheim | 17 | $247 |
| GSK | 17 | $246 |
| Sanofi-aventis U.S. LLC | 16 | $238 |
| Abbott | 9 | $217 |
| AbbVie(2 entities) | 12 | $196 |
| Johnson & Johnson | 13 | $196 |
| Neurocrine Biosciences, Inc. | 11 | $190 |
| Esperion Therapeutics, Inc. | 10 | $154 |
| Boston Scientific | 6 | $148 |
| UCB, Inc. | 6 | $95 |
| Lundbeck LLC | 4 | $75 |
| Biogen | 4 | $74 |
| Sunovion Pharmaceuticals Inc. | 7 | $61 |
| Amarin Pharma, Inc. | 4 | $59 |
| Phathom Pharmaceuticals, Inc. | 4 | $58 |
| Verona Pharma, Inc. | 3 | $58 |
| Exact Sciences | 2 | $53 |
| Xeris Pharmaceuticals, Inc. | 2 | $38 |
| Philips North America LLC | 2 | $27 |
| Merck | 2 | $24 |
| Kowa Pharmaceuticals America, Inc. | 1 | $20 |
| Otsuka America Pharmaceutical, Inc. | 1 | $19 |
| Bayer | 1 | $17 |
| Medtronic | 1 | $15 |
| Biohaven Pharmaceutical Holding Company Ltd. | 1 | $12 |
| Sumitomo Pharma America, Inc. | 1 | $6 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$8,665 in reported general payments places this provider in the 90th percentile of 5,182 internal medicine providers in Illinois.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 398 | $210,114 |
| JardianceEmpagliflozin | 184 | $126,883 |
| OzempicSemaglutide | 91 | $96,158 |
| TrulicityDulaglutide | 100 | $95,089 |
| XareltoRivaroxaban | 180 | $83,257 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 77 | $60,782 |
| NuplazidPimavanserin Tartrate | 12 | $59,957 |
| FarxigaDapagliflozin Propanediol | 62 | $43,572 |
| MyrbetriqMirabegron | 52 | $40,875 |
| RexultiBrexpiprazole | 56 | $40,443 |
| JanuviaSitagliptin Phosphate | 47 | $31,983 |
| MounjaroTirzepatide | 27 | $28,391 |
| Breo ElliptaFluticasone/Vilanterol | 52 | $25,638 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 54 | $20,256 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 38 | $18,318 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $622 | $210,114398 claims |
| Boehringer IngelheimJardiance, Tradjenta | $247 | $133,857197 claims |
| Lilly USA, LLCTrulicity, Mounjaro | $880 | $123,480127 claims |
| GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta, Arexvy | $246 | $112,277192 claims |
| Novo NordiskOzempic | $1,876 | $96,15891 claims |
| Johnson & JohnsonXarelto | $196 | $83,257180 claims |
| AstraZenecaFarxiga, Breztri Aerosphere, Symbicort | $733 | $56,21792 claims |
| Astellas Pharma US IncMyrbetriq | $409 | $40,87552 claims |
| Otsuka America Pharmaceutical, Inc.Rexulti | $19 | $40,44356 claims |
| MerckJanuvia, Dulera | $24 | $38,75968 claims |
| NovartisEntresto | $263 | $11,63330 claims |
| UCB, Inc.Briviact | $95 | $9,96914 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 5,182 internal medicine providers in Illinois.
Other internal medicine in Barry
- Dennis LevinsonChicago$25.3M
- Mary BrownRockford$16M
- Andrew BartlettChampaign$4.1M
- Danny SugimotoChicago$4M
- Peter O DonnellChicago$3.9M
- Daniel CatenacciChicago$3.5M
- Jeffrey GeohasEvanston$2.3M
- Patricia WalshChicago$2.1M
- Merle DiamondChicago$1.7M
- Yoko MomoyamaLombard$1.6M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.